- Beta blockers offer protection against disease progression in patients undergoing treatment with immune checkpoint inhibitors (ICIs) for NSCLC.
Why this matters
- Clinical and preclinical studies of some tumor types have found an association between the use of beta blockers and immunotherapy, but similar studies in patients with lung cancer were lacking.
- 109 patients receiving ICIs for NSCLC.
- Funding: None.
- 28 patients received concomitant beta blockers.
- Patients receiving beta blockers had better PFS (HR, 0.58; 95% CI, 0.36-0.93), but there was no significant difference between groups in OS.
- No difference in PFS between new or chronic beta blocker users.
- Patients with intracranial metastases who were receiving beta blockers had better OS (HR, 0.10; 95% CI, 0.04-0.30), but there was no difference in PFS.
- No significant difference in PFS or OS in patients receiving antidepressants, selective serotonin reuptake inhibitors, or benzodiazepines compared with patients who were not receiving these medications.
- Retrospective study.